vs
Side-by-side financial comparison of Fiverr International Ltd. (FVRR) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Fiverr International Ltd. is the larger business by last-quarter revenue ($287.8M vs $281.3M, roughly 1.0× Guardant Health, Inc.). Fiverr International Ltd. runs the higher net margin — 1.9% vs -45.7%, a 47.6% gap on every dollar of revenue. Fiverr International Ltd. produced more free cash flow last quarter ($52.1M vs $-54.2M). Over the past eight quarters, Fiverr International Ltd.'s revenue compounded faster (29.5% CAGR vs 29.2%).
Fiverr International Ltd. operates a global online freelance services marketplace connecting businesses and independent creators across over 160 countries. It offers services covering digital marketing, graphic design, programming, writing, video editing, and other professional fields, catering to SMEs, startups, and enterprise clients needing flexible on-demand talent solutions.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
FVRR vs GH — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $287.8M | $281.3M |
| Net Profit | $5.4M | $-128.5M |
| Gross Margin | 82.5% | 64.6% |
| Operating Margin | -3.5% | -43.0% |
| Net Margin | 1.9% | -45.7% |
| Revenue YoY | — | 39.4% |
| Net Profit YoY | — | -15.8% |
| EPS (diluted) | — | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $281.3M | ||
| Q3 25 | $287.8M | $265.2M | ||
| Q2 25 | $188.2M | $232.1M | ||
| Q1 25 | $93.5M | $203.5M | ||
| Q4 24 | — | $201.8M | ||
| Q3 24 | $269.9M | $191.5M | ||
| Q2 24 | $177.3M | $177.2M | ||
| Q1 24 | $88.0M | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $5.4M | $-92.7M | ||
| Q2 25 | $4.1M | $-99.9M | ||
| Q1 25 | $788.0K | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | $-1.0M | $-107.8M | ||
| Q2 24 | $-4.0M | $-102.6M | ||
| Q1 24 | $-4.3M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | 82.5% | 64.7% | ||
| Q2 25 | 83.3% | 65.0% | ||
| Q1 25 | 83.5% | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | 82.8% | 61.1% | ||
| Q2 24 | 82.4% | 59.1% | ||
| Q1 24 | 82.2% | 61.2% |
| Q4 25 | — | -43.0% | ||
| Q3 25 | -3.5% | -37.3% | ||
| Q2 25 | -3.4% | -45.9% | ||
| Q1 25 | -4.4% | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | -5.0% | -61.3% | ||
| Q2 24 | -6.3% | -56.8% | ||
| Q1 24 | -8.1% | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | 1.9% | -35.0% | ||
| Q2 25 | 2.2% | -43.0% | ||
| Q1 25 | 0.8% | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | -0.4% | -56.3% | ||
| Q2 24 | -2.3% | -57.9% | ||
| Q1 24 | -4.9% | -68.2% |
| Q4 25 | — | $-1.01 | ||
| Q3 25 | — | $-0.74 | ||
| Q2 25 | — | $-0.80 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | $-0.90 | ||
| Q3 24 | — | $-0.88 | ||
| Q2 24 | — | $-0.84 | ||
| Q1 24 | — | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.5M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $362.6M | $-99.3M |
| Total Assets | $1.1B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | $133.5M | $580.0M | ||
| Q2 25 | $578.4M | $629.1M | ||
| Q1 25 | $133.5M | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | $183.7M | $585.0M | ||
| Q2 24 | $183.7M | $933.7M | ||
| Q1 24 | $183.7M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-99.3M | ||
| Q3 25 | $362.6M | $-354.5M | ||
| Q2 25 | $404.9M | $-305.5M | ||
| Q1 25 | $362.6M | $-250.8M | ||
| Q4 24 | — | $-139.6M | ||
| Q3 24 | $355.8M | $-60.1M | ||
| Q2 24 | $355.8M | $-1.6M | ||
| Q1 24 | $355.8M | $68.3M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $1.0B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.0M | $-26.4M |
| Free Cash FlowOCF − Capex | $52.1M | $-54.2M |
| FCF MarginFCF / Revenue | 18.1% | -19.3% |
| Capex IntensityCapex / Revenue | 0.3% | 9.9% |
| Cash ConversionOCF / Net Profit | 9.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | $124.9M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.4M | ||
| Q3 25 | $53.0M | $-35.4M | ||
| Q2 25 | $42.2M | $-60.3M | ||
| Q1 25 | $21.2M | $-62.7M | ||
| Q4 24 | — | $-64.5M | ||
| Q3 24 | $10.9M | $-51.1M | ||
| Q2 24 | $32.2M | $-94.0M | ||
| Q1 24 | $21.2M | $-30.3M |
| Q4 25 | — | $-54.2M | ||
| Q3 25 | $52.1M | $-45.8M | ||
| Q2 25 | $41.5M | $-65.9M | ||
| Q1 25 | $20.8M | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | $10.6M | $-55.3M | ||
| Q2 24 | $31.5M | $-99.1M | ||
| Q1 24 | $20.8M | $-37.2M |
| Q4 25 | — | -19.3% | ||
| Q3 25 | 18.1% | -17.3% | ||
| Q2 25 | 22.0% | -28.4% | ||
| Q1 25 | 22.3% | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | 3.9% | -28.9% | ||
| Q2 24 | 17.8% | -55.9% | ||
| Q1 24 | 23.7% | -22.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | 0.3% | 3.9% | ||
| Q2 25 | 0.4% | 2.4% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | 0.1% | 2.2% | ||
| Q2 24 | 0.4% | 2.9% | ||
| Q1 24 | 0.4% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 9.81× | — | ||
| Q2 25 | 10.40× | — | ||
| Q1 25 | 26.90× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVRR
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
